Skip to content

The value of Sonazoid contrast agent with Kupffer phase in the diagnosis of focal liver lesions by contrast-enhanced ultrasound

The value of Sonazoid contrast agent with Kupffer phase in the diagnosis of focal liver lesions by contrast-enhanced ultrasound

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000039018
Enrollment
Unknown
Registered
2020-10-13
Start date
2020-10-15
Completion date
Unknown
Last updated
2021-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Focal liver lesions

Interventions

Gold Standard:Pathological diagnosis of surgically resected or biopsy of focal liver lesions
Index test:Sonozoid&#32
ultrasound&#32
diagnosis

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Focal liver lesions (not simple cystic lesions) found on ultrasound,CT and MRI,patients are admitted to the hospital for surgery or biopsy. 2. Aged >= 18 years.

Exclusion criteria

Exclusion criteria: 1. Local treatments for focal liver lesions have been performed (including transcatheter arterial chemoembolization, Radiofrequency ablation, Microwave ablation,etc.). 2. Patients who are allergic to eggs,egg products,and contrast agents. 3. Recently have acute coronary syndrome and unstable ischemic heart disease. 4. A history of adult respiratory distress syndrome, severe emphysema, acute pulmonary vasculitis or pulmonary embolism. 5. The patient cannot cooperate to complete the examination.

Design outcomes

Primary

MeasureTime frame
sensitivity;specificity;positive predictive value;negative predictive value;

Countries

China

Contacts

Public ContactQiang Lu

West China Hospital of Sichuan University

wsluqiang@126.com+86 18980606310

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026